NovaBridge Biosciences — Revenue by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/32830812-e999-49ef-a51b-3b035831dfc4/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $632.0k | 2023-01-01 – 2023-12-31 | evidence 0000950170-25-050344 |
| FY 2022 | $-1.6M | 2022-01-01 – 2022-12-31 | evidence 0000950170-25-050344 |
| FY 2021 | — | 2021-01-01 – 2021-12-31 | evidence 0001104659-23-053462 |
| FY 2020 | — | 2020-01-01 – 2020-12-31 | evidence 0001104659-23-053462 |
| FY 2019 | $4.3M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-124785 |
| FY 2018 | — | 2018-01-01 – 2018-12-31 | evidence 0001193125-20-124785 |
| FY 2017 | — | 2017-01-01 – 2017-12-31 | evidence 0001193125-20-124785 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NovaBridge Biosciences — all facts · Net Income · Operating Income